Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating
Yahoo Finance · Oct 12, 2026 · Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Investing.com -- Contineum Therapeutics (NASDAQ:CTNM) shares reversed course and fell 25% in Monday trading, erasing an initial 27% pre-market surge following Bristol Myers Squibb’s (BMY) announcement that its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis (IPF) met its primary endpoint.
Not investment advice. Headline and summary only, not a full reprint.